Stay in touch
Prime news from our network.
#read
SCHOTT Pharma closes 2024 with record growth and strong margin
SCHOTT Pharma, the leading supplier of pharmaceutical packaging and delivery systems, has successfully completed the 2024 financial year and achieved all its targets.
12/12/2024
Annual sales rose to 957 million euros, which corresponds to currency-adjusted growth of 12 per cent. Particularly noteworthy is the record EBITDA margin of 27.8 per cent, which was driven by the strong demand for High Value Solutions (HVS), which account for 55 per cent of total sales.
In the fourth quarter, the company generated sales of 237 million euros and significantly exceeded the previous year's result with an EBITDA margin of 27.9 per cent. Growth was driven by innovations such as optimised ready-to-use cartridges and strong momentum in the prefillable glass syringe segment.For 2025, SCHOTT Pharma expects further sales and earnings growth. The company continues to focus on innovation and expansion to serve long-term market trends such as subcutaneous drug delivery and sustainable production processes.
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.